Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.
Obes Surg · 2025
Last updated 2026-05-28A review of six studies involving 300 participants found that taking semaglutide after bariatric surgery led to significant weight loss, with an average reduction of about 15.73 units compared to those not taking the drug. The results were consistent even when tested for reliability.
AI summary of the abstract below.
| Journal | Obes Surg, 2025 |
|---|---|
| Citations | 3 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
BACKGROUND: A significant number of patients encounter weight gain (WG) or inadequate weight loss (IWL) following bariatric surgery for obesity. Recent studies have explored the role of semaglutide in addressing weight management challenges in patients who have inadequate weight loss or weight gain after bariatric surgery. Despite such studies, a systematic review and meta-analysis evaluating the efficacy, safety and tolerability of semaglutide in this specific clinical context remains absent. Therefore, this study was undertaken to address this knowledge gap.
METHODS: Databases were searched for randomized controlled trials (RCTs), case-control, cohort and observational studies involving use of semaglutide in the intervention arm post-bariatric surgery. Outcome was weight loss post-bariatric surgery.
RESULTS: A total of six studies (300 participants) demonstrated significant weight reduction following semaglutide administration after bariatric surgery (WMD: - 15.730, 95% CI: - 22.140, - 9.320, p < 0.001). This effect remained robust in sensitivity analysis.
CONCLUSION: The current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.
Verbatim abstract via PubMed 40418526 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.